Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Human IL-15 Protein, Fc Tag, premium grade (Cat. No. IL5-H5257) stimulates proliferation of CTLL-2 cells. The typically EC50 for this effect is 2.483 ng/mL(QC tested).
Human IL-15, premium grade (Cat. No. IL5-H5215) stimulates proliferation of CTLL-2 cells. The typically EC50 for this effect is 0.6068 ng/mL, corresponding to a specific activity of > 0.8ⅹ10^7 IU/mg, which is calibrated against human IL- 15 WHO International Standard (NIBSC code: 95/554) (QC tested).
Biotinylated Human IL-15 R alpha, Fc,Avitag (Cat. No. ILA-H82F4) immobilized on CM5 Chip can bind Human IL-15 Protein, Fc Tag, premium grade (Cat. No. IL5-H5257) with an affinity constant of 27.7 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Heterodimeric interleukin 15(Novartis Pharma) | NIZ-985 | Novartis Pharma Ag | Details | ||
| SAR-441000 | SAR441000; SAR-441000; BNT-131 | Phase 1 Clinical | Biontech Se, Sanofi | Neoplasm Metastasis | Details |
| CAR-5/IL-15-transduced CB-NK cell therapy | Phase 2 Clinical | MD Anderson Cancer Center | Hematologic Neoplasms | Details | |
| Ordesekimab | HuMab-IL15; AMG-714; PRV-015 | Phase 2 Clinical | Provention Bio Inc, Genmab A/S, Amgen Inc | Arthritis, Rheumatoid; Psoriasis; Celiac Disease; Vitiligo | Details |
| CYTO-102 | CYTO-NK-102; CYTO-102; COH06 | Phase 1 Clinical | CytoImmune Therapeutics Inc | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| CALY-002 | Phase 1 Clinical | Calypso Biotech Bv | Celiac Disease; Eosinophilic Esophagitis | Details | |
| RTX-240 | RTX-240 | Phase 2 Clinical | Rubius Therapeutics Inc | Leukemia, Promyelocytic, Acute | Details |
| Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus(CNBG) | VG-161 | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Liver Neoplasms; Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Cholangiocarcinoma; Carcinoma, Hepatocellular | Details |
| EQ101 | EQ101 | Phase 2 Clinical | Equillium Inc | Alopecia; Alopecia Areata | Details |
| SIM-0237 | SIM-0237 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours | Details |
| XmAb24306 | XmAb-24306; RG-6323; RO-7310729; XmAb-306 | Phase 1 Clinical | Genentech Inc, Xencor Inc | Solid tumours; Neoplasms; Multiple Myeloma | Details |
| HCW-9218 | HCW-9218 | Phase 2 Clinical | HCW Biologics Inc | Solid tumours; Pancreatic Neoplasms; Pulmonary Fibrosis | Details |
This web search service is supported by Google Inc.
A-Z
